Karyopharm Therapeutics (KPTI) Competitors $4.62 +0.01 (+0.22%) Closing price 07/3/2025 02:45 PM EasternExtended Trading$4.49 -0.13 (-2.81%) As of 07/3/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. BIOA, IKT, BDTX, ALEC, TIL, GALT, LXEO, KYTX, RAPT, and LYELShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include BioAge Labs (BIOA), Inhibikase Therapeutics (IKT), Black Diamond Therapeutics (BDTX), Alector (ALEC), Instil Bio (TIL), Galectin Therapeutics (GALT), Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors BioAge Labs Inhibikase Therapeutics Black Diamond Therapeutics Alector Instil Bio Galectin Therapeutics Lexeo Therapeutics Kyverna Therapeutics Rapt Therapeutics Lyell Immunopharma BioAge Labs (NASDAQ:BIOA) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership. Is BIOA or KPTI more profitable? BioAge Labs has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -43.99%. Company Net Margins Return on Equity Return on Assets BioAge LabsN/A N/A N/A Karyopharm Therapeutics -43.99%N/A -35.95% Does the media favor BIOA or KPTI? In the previous week, Karyopharm Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for BioAge Labs. Karyopharm Therapeutics' average media sentiment score of 0.00 beat BioAge Labs' score of -0.17 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of BIOA or KPTI? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate BIOA or KPTI? Karyopharm Therapeutics has a consensus price target of $43.20, suggesting a potential upside of 835.06%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, BIOA or KPTI? BioAge Labs has higher earnings, but lower revenue than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/AKaryopharm Therapeutics$145.24M0.27-$76.42M-$13.26-0.35 SummaryKaryopharm Therapeutics beats BioAge Labs on 7 of the 11 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.93M$2.43B$5.56B$9.05BDividend YieldN/A1.78%5.24%3.99%P/E Ratio-0.359.0227.6520.23Price / Sales0.27680.43419.56119.26Price / CashN/A21.7726.2128.59Price / Book-0.214.558.035.65Net Income-$76.42M$31.26M$3.18B$249.15M7 Day Performance5.24%3.25%2.93%3.28%1 Month Performance2.90%3.46%1.72%3.95%1 Year Performance-62.38%0.77%34.39%20.98% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.8352 of 5 stars$4.62+0.2%$43.20+835.1%-62.4%$37.93M$145.24M-0.35380BIOABioAge LabsN/A$4.13-1.7%N/AN/A$148.06MN/A0.00N/AIKTInhibikase Therapeutics1.3505 of 5 stars$1.95+20.4%$6.50+233.3%+62.9%$144.97M$260K-0.736News CoverageBDTXBlack Diamond Therapeutics3.1219 of 5 stars$2.48+5.5%$14.60+488.7%-42.3%$141.01MN/A41.3390Positive NewsAnalyst UpgradeALECAlector3.8331 of 5 stars$1.40-5.4%$4.00+185.7%-66.4%$139.99M$100.56M-1.11270TILInstil Bio2.6075 of 5 stars$20.83-9.3%$119.00+471.3%+185.4%$136.62MN/A-1.74410News CoverageGALTGalectin Therapeutics1.6392 of 5 stars$2.11-9.4%$6.00+184.4%+4.6%$133.54MN/A-2.939Gap UpLXEOLexeo Therapeutics1.8815 of 5 stars$4.02-2.4%$16.60+312.9%-71.4%$133.46M$650K-1.2258KYTXKyverna Therapeutics1.2706 of 5 stars$3.07-6.4%$18.50+502.6%-58.7%$132.69M$7.03M-0.9196Gap DownRAPTRapt Therapeutics4.2263 of 5 stars$8.00-5.1%$24.00+200.0%-63.7%$132.32M$1.53M-0.4280LYELLyell Immunopharma2.5899 of 5 stars$8.84-1.1%$15.00+69.7%-67.5%$130.92M$60K-0.35270 Related Companies and Tools Related Companies BioAge Labs Competitors Inhibikase Therapeutics Competitors Black Diamond Therapeutics Competitors Alector Competitors Instil Bio Competitors Galectin Therapeutics Competitors Lexeo Therapeutics Competitors Kyverna Therapeutics Competitors Rapt Therapeutics Competitors Lyell Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
